Estimated cost-savings from optimizing use of inhaled medications for inpatients with obstructive lung disease

Ryuhei Kondo; Jennifer Austin; Mary Akel; Vineet M Arora; Valerie G Press

doi:10.1080/02770903.2022.2047718

Estimated cost-savings from optimizing use of inhaled medications for inpatients with obstructive lung disease

J Asthma. 2023 Feb;60(2):323-330. doi: 10.1080/02770903.2022.2047718. Epub 2022 Mar 10.

Authors

Ryuhei Kondo¹, Jennifer Austin², Mary Akel³, Vineet M Arora³, Valerie G Press³

Affiliations

¹ Integral Corporation and The University of Chicago Booth School of Business, Chicago, IL, USA.
² Department of Pharmacy, The Johns Hopkins Medicine, Baltimore, MD, USA.
³ Department of Medicine, Section of General Internal Medicine, University of Chicago, Chicago, IL, USA.

Abstract

Models representing transitions from all-nebulized to nebulizer-plus-MDI respiratory medications resulted in cost savings, largely from the reduction of labor cost of nebulizer administration with nebs-only treatment. Therefore, transitioning from nebs to MDIs can lead to cost savings and could allow greater opportunities for inhaler education.

Keywords: COPD; High-value care; asthma; metered dose inhalers; patient education; self-management.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Administration, Inhalation
Asthma* / drug therapy
Cost Savings
Humans
Inpatients
Metered Dose Inhalers
Nebulizers and Vaporizers
Pulmonary Disease, Chronic Obstructive* / drug therapy

Abstract

Publication types

MeSH terms

Grants and funding